CO2017011851A2 - Novel compounds - Google Patents
Novel compoundsInfo
- Publication number
- CO2017011851A2 CO2017011851A2 CONC2017/0011851A CO2017011851A CO2017011851A2 CO 2017011851 A2 CO2017011851 A2 CO 2017011851A2 CO 2017011851 A CO2017011851 A CO 2017011851A CO 2017011851 A2 CO2017011851 A2 CO 2017011851A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- novel compounds
- rip2 kinase
- diseases
- compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 101001109137 Homo sapiens Receptor-interacting serine/threonine-protein kinase 2 Proteins 0.000 abstract 3
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a compuestos, composiciones, combinaciones y medicamentos que contienen dichos compuestos y a procedimientos para su preparación. La invención también se refiere al uso de dichos compuestos, combinaciones, composiciones y medicamentos, por ejemplo como inhibidores de la actividad de cinasa RIP2, incluyendo la degradación de cinasa RIP2, el tratamiento de enfermedades y estados mediados por la cinasa RIP2, en particular para el tratamiento de enfermedades o estados inflamatorios.The present invention relates to compounds, compositions, combinations and medicaments containing said compounds and to methods for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, for example as inhibitors of RIP2 kinase activity, including the degradation of RIP2 kinase, the treatment of diseases and conditions mediated by RIP2 kinase, in particular for the treatment of diseases or inflammatory conditions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506872.9A GB201506872D0 (en) | 2015-04-22 | 2015-04-22 | Novel compounds |
| PCT/US2016/028332 WO2016172134A2 (en) | 2015-04-22 | 2016-04-20 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017011851A2 true CO2017011851A2 (en) | 2018-02-09 |
Family
ID=53299021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0011851A CO2017011851A2 (en) | 2015-04-22 | 2017-11-21 | Novel compounds |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10435391B2 (en) |
| EP (1) | EP3286169B1 (en) |
| JP (1) | JP2018513867A (en) |
| KR (1) | KR20170139096A (en) |
| CN (1) | CN107709305B (en) |
| AU (1) | AU2016252404B2 (en) |
| BR (1) | BR112017022604A2 (en) |
| CA (1) | CA2983414A1 (en) |
| CL (1) | CL2017002650A1 (en) |
| CO (1) | CO2017011851A2 (en) |
| CR (1) | CR20170478A (en) |
| EA (1) | EA033343B1 (en) |
| ES (1) | ES2841548T3 (en) |
| GB (1) | GB201506872D0 (en) |
| HK (1) | HK1243410A1 (en) |
| IL (1) | IL255067A0 (en) |
| MX (1) | MX375674B (en) |
| PE (1) | PE20180044A1 (en) |
| PH (1) | PH12017501921A1 (en) |
| SG (1) | SG11201708311UA (en) |
| WO (1) | WO2016172134A2 (en) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102438072B1 (en) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase |
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US10071164B2 (en) * | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| BR112017015497A2 (en) | 2015-01-20 | 2018-01-30 | Arvinas, Inc. | compound and composition |
| US10730870B2 (en) | 2015-03-18 | 2020-08-04 | Arvinas Operations, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | COMPOUNDS AND METHODS FOR THE TARGETED REMOVAL OF BROMO-DOMAIN-CONTAINING PROTEINS |
| CN109311867A (en) * | 2016-04-20 | 2019-02-05 | 葛兰素史克知识产权开发有限公司 | Conjugates comprising RIPK2 inhibitors |
| EP3512842B1 (en) | 2016-09-15 | 2024-01-17 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| KR20250044800A (en) | 2016-10-11 | 2025-04-01 | 아비나스 오퍼레이션스, 인코포레이티드 | Compounds and methods for the targeted degradation of androgen receptor |
| MX2019005007A (en) | 2016-11-01 | 2019-07-18 | Arvinas Inc | PROTAC TARGETED AT TAU PROTEIN AND ASSOCIATED METHODS OF USE. |
| PL3689868T3 (en) | 2016-12-01 | 2024-03-11 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
| WO2018118598A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| AU2017382436C1 (en) | 2016-12-23 | 2021-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of Rapidly Accelerated Fibrosarcoma polypeptides |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| BR112019012682A2 (en) | 2016-12-23 | 2019-12-17 | Arvinas Operations Inc | chimeric molecules targeting egfr proteolysis and associated methods of use |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| BR112019015312A2 (en) | 2017-01-26 | 2020-03-10 | Arvinas Operations, Inc. | MODULATORS OF PROTEOLYSIS BY THE ESTROGEN RECEPTOR AND ASSOCIATED METHODS OF USE |
| WO2018144649A1 (en) | 2017-01-31 | 2018-08-09 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| CN107987083A (en) * | 2017-11-24 | 2018-05-04 | 江苏亚盛医药开发有限公司 | For treating and/or preventing double diazabicyclo compounds of relevant with hepatitis viruse disease or illness |
| WO2019148055A1 (en) | 2018-01-26 | 2019-08-01 | Yale University | Imide-based modulators of proteolysis and methods of use |
| US11161841B2 (en) | 2018-04-04 | 2021-11-02 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| WO2020027225A1 (en) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | Heterocyclic compound |
| WO2020041331A1 (en) | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| CN112638905A (en) * | 2018-08-28 | 2021-04-09 | 南京明德新药研发有限公司 | Quinazoline derivatives as RIP2 kinase inhibitors |
| US11547759B2 (en) | 2019-01-30 | 2023-01-10 | Montelino Therapeutics, Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| JP7555938B2 (en) | 2019-01-30 | 2024-09-25 | モンテリノ・セラピューティクス・インコーポレイテッド | Bifunctional compounds and methods for targeted ubiquitination of the androgen receptor |
| CN113747925B (en) | 2019-03-21 | 2024-10-15 | 隆萨销售股份公司 | Extracellular vesicle conjugates and uses thereof |
| US12233356B2 (en) | 2019-03-21 | 2025-02-25 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
| JP2021024787A (en) | 2019-07-31 | 2021-02-22 | ファイメクス株式会社 | Heterocyclic compound |
| JP7764027B2 (en) | 2019-07-31 | 2025-11-05 | ファイメクス株式会社 | heterocyclic compounds |
| IL320609A (en) | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| CA3154386A1 (en) | 2019-10-17 | 2021-04-22 | Michael Berlin | Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety |
| CR20220353A (en) | 2019-12-19 | 2022-10-20 | Arvinas Operations Inc | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF THE ANDROGEN RECEPTOR |
| JP2023524599A (en) | 2020-05-09 | 2023-06-12 | アルビナス・オペレーションズ・インコーポレイテッド | Methods of making bifunctional compounds, ultrapure forms of bifunctional compounds, and dosage forms containing them |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| PE20231555A1 (en) | 2020-09-14 | 2023-10-03 | Arvinas Operations Inc | CRYSTALLINE AND AMORPHOUS FORMS OF A COMPOUND FOR THE DIRECTED DEGRADATION OF THE ESTROGEN RECEPTOR |
| TW202227427A (en) * | 2020-09-16 | 2022-07-16 | 美商拜歐斯瑞克斯公司 | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| WO2022197862A1 (en) * | 2021-03-17 | 2022-09-22 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| AU2022259683A1 (en) | 2021-04-16 | 2023-10-19 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| US11981672B2 (en) | 2021-09-13 | 2024-05-14 | Montelino Therapeutics Inc. | Bi-functional compounds and methods for targeted ubiquitination of androgen receptor |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
| WO2023180388A1 (en) | 2022-03-24 | 2023-09-28 | Glaxosmithkline Intellectual Property Development Limited | 2,4-dioxotetrahydropyrimidinyl derivatives as degrons in protacs |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| CN115869308B (en) * | 2022-12-30 | 2024-03-26 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | Application of a small molecule compound in the preparation of anti-colorectal cancer drugs |
| AU2024212035A1 (en) | 2023-01-26 | 2025-08-14 | Arvinas Operations, Inc. | Cereblon-based kras degrading protacs ans uses related thereto |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| WO2025092821A1 (en) * | 2023-11-01 | 2025-05-08 | 成都赜灵生物医药科技有限公司 | Quinazoline derivative ripk2 inhibitor and use thereof |
| TW202535392A (en) | 2023-12-08 | 2025-09-16 | 美商亞文納營運公司 | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004005248A1 (en) * | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| MX2007000490A (en) * | 2004-07-12 | 2007-06-11 | Idun Pharmaceuticals Inc | Tetrapeptide analogs. |
| US8278293B2 (en) * | 2007-04-13 | 2012-10-02 | The Regents Of The University Of Michigan | Diazo bicyclic Smac mimetics and the uses thereof |
| AR066348A1 (en) | 2007-04-30 | 2009-08-12 | Genentech Inc | IAP INHIBITORS |
| US20110117081A1 (en) * | 2008-05-05 | 2011-05-19 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
| US8815927B2 (en) | 2009-10-23 | 2014-08-26 | The Regents Of The University Of Michigan | Bivalent diazo bicyclic Smac mimetics and the uses thereof |
| ES2552977T3 (en) | 2010-05-07 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolines as kinase inhibitors |
| UY33549A (en) | 2010-08-10 | 2012-01-31 | Glaxo Group Ltd | QUINOLIL AMINAS AS INHIBITING AGENTS OF KINASES |
| SG192769A1 (en) | 2011-03-04 | 2013-09-30 | Glaxosmithkline Ip No 2 Ltd | Amino-quinolines as kinase inhibitors |
| TWI547494B (en) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | Aminoquinazolines as kinase inhibitors |
| KR102438072B1 (en) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | Compounds and Methods for the Enhanced Degradation of Targeted Proteins and Other Polypeptides by an E3 Ubiquitin Ligase |
| MX366130B (en) | 2012-08-23 | 2019-06-28 | Univ Michigan Regents | Bivalent inhibitors of iap proteins and therapeutic methods using the same. |
| AR092529A1 (en) * | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | AMINOQUINAZOLINE COMPOUND, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOSITE FOR THE PREPARATION OF A MEDICINAL PRODUCT |
| AR092530A1 (en) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | AMINO-QUINOLINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOUND FOR THE PREPARATION OF A MEDICINAL PRODUCT |
| EP2897949B1 (en) | 2012-09-18 | 2018-01-10 | Bristol-Myers Squibb Company | Iap antagonists |
| US9603889B2 (en) | 2012-10-02 | 2017-03-28 | Bristol-Myers Squibb Company | IAP antagonists |
| CA2887497A1 (en) | 2012-12-11 | 2014-06-19 | Steven Gregory Mischke | Dimeric compounds |
| TWI630203B (en) | 2013-02-21 | 2018-07-21 | 葛蘭素史克智慧財產發展有限公司 | Quinazolines as kinase inhibitors |
| WO2015160845A2 (en) | 2014-04-14 | 2015-10-22 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| AU2015261812B2 (en) | 2014-05-23 | 2019-11-21 | F. Hoffmann-La Roche Ag | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors |
| WO2016037026A1 (en) | 2014-09-05 | 2016-03-10 | Merck Patent Gmbh | Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| MX380940B (en) | 2015-04-22 | 2025-03-11 | Rigel Pharmaceuticals Inc | PYRAZOLE COMPOUNDS AND METHOD FOR PREPARING AND USING THE COMPOUNDS. |
| GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| TW201642860A (en) | 2015-04-22 | 2016-12-16 | 塞爾基因定量細胞研究公司 | Bromo domain inhibitor |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CN109311867A (en) * | 2016-04-20 | 2019-02-05 | 葛兰素史克知识产权开发有限公司 | Conjugates comprising RIPK2 inhibitors |
-
2015
- 2015-04-22 GB GBGB1506872.9A patent/GB201506872D0/en not_active Ceased
-
2016
- 2016-04-20 CA CA2983414A patent/CA2983414A1/en not_active Abandoned
- 2016-04-20 HK HK18102883.6A patent/HK1243410A1/en unknown
- 2016-04-20 PE PE2017002302A patent/PE20180044A1/en unknown
- 2016-04-20 EA EA201792047A patent/EA033343B1/en not_active IP Right Cessation
- 2016-04-20 CR CR20170478A patent/CR20170478A/en unknown
- 2016-04-20 EP EP16783708.7A patent/EP3286169B1/en active Active
- 2016-04-20 MX MX2017013556A patent/MX375674B/en active IP Right Grant
- 2016-04-20 ES ES16783708T patent/ES2841548T3/en active Active
- 2016-04-20 WO PCT/US2016/028332 patent/WO2016172134A2/en not_active Ceased
- 2016-04-20 KR KR1020177033407A patent/KR20170139096A/en not_active Withdrawn
- 2016-04-20 US US15/568,025 patent/US10435391B2/en not_active Expired - Fee Related
- 2016-04-20 SG SG11201708311UA patent/SG11201708311UA/en unknown
- 2016-04-20 CN CN201680036813.3A patent/CN107709305B/en not_active Expired - Fee Related
- 2016-04-20 AU AU2016252404A patent/AU2016252404B2/en not_active Ceased
- 2016-04-20 JP JP2017555322A patent/JP2018513867A/en not_active Ceased
- 2016-04-20 BR BR112017022604-9A patent/BR112017022604A2/en not_active Application Discontinuation
-
2017
- 2017-10-16 IL IL255067A patent/IL255067A0/en unknown
- 2017-10-18 CL CL2017002650A patent/CL2017002650A1/en unknown
- 2017-10-20 PH PH12017501921A patent/PH12017501921A1/en unknown
- 2017-11-21 CO CONC2017/0011851A patent/CO2017011851A2/en unknown
-
2019
- 2019-08-22 US US16/547,734 patent/US20190382381A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN107709305B (en) | 2020-09-29 |
| SG11201708311UA (en) | 2017-11-29 |
| MX2017013556A (en) | 2018-08-01 |
| CR20170478A (en) | 2018-01-22 |
| PH12017501921A1 (en) | 2018-03-19 |
| WO2016172134A2 (en) | 2016-10-27 |
| CA2983414A1 (en) | 2016-10-27 |
| IL255067A0 (en) | 2017-12-31 |
| CL2017002650A1 (en) | 2018-03-16 |
| MX375674B (en) | 2025-03-06 |
| ES2841548T3 (en) | 2021-07-08 |
| GB201506872D0 (en) | 2015-06-03 |
| KR20170139096A (en) | 2017-12-18 |
| AU2016252404B2 (en) | 2018-07-26 |
| JP2018513867A (en) | 2018-05-31 |
| WO2016172134A3 (en) | 2016-12-01 |
| HK1243410A1 (en) | 2018-07-13 |
| EP3286169A2 (en) | 2018-02-28 |
| EA201792047A1 (en) | 2018-04-30 |
| EA033343B1 (en) | 2019-09-30 |
| PE20180044A1 (en) | 2018-01-15 |
| US20180134688A1 (en) | 2018-05-17 |
| AU2016252404A1 (en) | 2017-12-07 |
| CN107709305A (en) | 2018-02-16 |
| EP3286169A4 (en) | 2018-11-21 |
| EP3286169B1 (en) | 2020-10-07 |
| US10435391B2 (en) | 2019-10-08 |
| US20190382381A1 (en) | 2019-12-19 |
| BR112017022604A2 (en) | 2018-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017011851A2 (en) | Novel compounds | |
| NI201600144A (en) | QUINOXALINE DERIVATIVES USEFUL AS MODULATORS OF FGFR KINASE | |
| CL2017001204A1 (en) | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | |
| BR112016023558A2 (en) | compounds useful as immunomodulators | |
| MX2016015743A (en) | Cyclopropylamine compounds as histone demethylase inhibitors. | |
| MX383164B (en) | COMPOSITION CONTAINING RNA FOR THE TREATMENT OF TUMOR DISEASES. | |
| MX2016008131A (en) | Bicyclic heterocycle compounds and their uses in therapy. | |
| NI201300073A (en) | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF TRK | |
| MX386935B (en) | PRODRUGS OF FUMARATES AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES. | |
| UY34955A (en) | 4-METHYL-2,3,5,9,9B-PENTAAZA-CICLOPENTA [A] NAFTALENOS | |
| BR112017004741A2 (en) | compounds and compositions as raf kinase inhibitors | |
| BR112016028845A2 (en) | compound, pharmaceutical composition and use of a compound | |
| DOP2016000253A (en) | NEW COMPOUNDS | |
| BR112018014590A2 (en) | formulations / compositions comprising a btk inhibitor | |
| MX2016012784A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions. | |
| UY35747A (en) | SUBSTITUTED DERIVATIVES OF PHENYLALANINE | |
| DOP2016000312A (en) | COMPOUNDS DERIVED FROM 1- (CICLOPENT-2-EN-1-IL) -3- (2-HIDROXI-3- (ARILSULFONIL) PHENYL) UREA AS CXCR2 INHIBITORS | |
| CR20170513A (en) | USEFUL PIRAZOL DERIVATIVES AS INHIBITORS OF 5-LI-POXIGENASA ACTIVATING PROTEIN (FLAP). | |
| MX2017013137A (en) | Chromene derivatives as phoshoinositide 3-kinases inhibitors. | |
| BR112017006552A2 (en) | compositions and methods for inhibiting the biological activity of soluble biomolecules | |
| DOP2019000221A (en) | DERIVATIVES OF PIRAZOLE AS BROMODOMINIUM INHIBITORS | |
| BR112016018418A2 (en) | COMPOUND, USE THEREOF, AND PHARMACEUTICAL COMPOSITION | |
| UY35745A (en) | SUBSTITUTED DERIVATIVES OF PHENYLALANINE | |
| UY37729A (en) | NEW COMPOUNDS THAT INHIBIT THE ACTIVITY OF Nav1.7 | |
| DOP2016000251A (en) | WNT SIGNALING ROAD INHIBITORS |